Innovations in Cancer Research and Treatment

Md Shamsuddin Sultan Khan [1]*, Tufael [2]

Abstract

Cancer remains a significant global health challenge, with rising incidence rates projected in the coming years. This study delves into the dynamic field of cancer therapy, particularly focusing on targeted modalities such as immunotherapy, cancer vaccines, and stem cell-based treatments. Emphasizing the importance of personalized medicine, we explore how tailored approaches can enhance patient outcomes and alleviate the burden of cancer. Examining recent advancements in targeted therapy, including monoclonal antibodies and immune checkpoint inhibitors, we showcase the transformative potential of precision oncology in reshaping cancer care. Tackling hurdles like treatment resistance and equitable access to novel therapies, we outline future research avenues. Through an interdisciplinary lens integrating genetics, immunology, and therapeutic innovation, we aspire to advance towards a future where cancer no longer poses a pervasive threat to global health.

Significance | Investigation into targeted therapy innovations and personalized medicine provides valuable insights for enhancing cancer treatment efficacy and mitigating its global impact.

*Correspondence. Md Shamsuddin Sultan Khan, Independent Researcher, Miami Beach, Fl 33139, USA.
E-mail: jupitex@gmail.com

Editor Loiy Elsir Ahmed Hassan, Ph.D., And accepted by the Editorial Board Feb 23, 2024 (received for review Jan 05, 2024)

Keywords: Cancer therapy, targeted therapy, immunotherapy, personalized medicine, precision oncology.

Introduction

Cancer, as one of the foremost causes of mortality globally, continues to exert a significant burden on healthcare systems and societies worldwide. This burden is reflected in the staggering number of new cases and deaths reported annually. According to Sung et al. (2021), the incidence of cancer has been steadily increasing, with projections indicating a further rise in the coming years. The Global Burden of Cancer (GLOBOCON) 2020 estimates, as reported by Kulkarni et al. (2022), paint a grim picture, suggesting that the number of new cancer cases reached 19.3 million in 2020, with 10 million deaths recorded globally. Furthermore, these estimates predict a substantial increase in the cancer burden, with the number of cases expected to surge to 28.4 million by 2040—a 47% rise from 2020 figures.

The distribution of cancer types varies across regions and populations. However, breast cancer emerges as the most frequently diagnosed cancer worldwide, followed by lung, colorectal, prostate, and stomach cancers, as highlighted by Kulkarni et al. (2022). This distribution is mirrored in the mortality rates, with breast cancer being the leading cause of cancer-related deaths among females, while lung cancer tops the list for males (Sung et al., 2021).

The impact of cancer is not uniform across all demographics. Figure 1 illustrates the projected cancer burden globally, indicating a disproportionate increase in the burden among females compared to males (Smith et al., 2019). This gender disparity underscores the need for targeted interventions and tailored healthcare strategies to address the evolving landscape of cancer prevalence.

Traditionally, cancer treatment has relied on a combination of modalities, including surgery, radiation therapy, and

Author Affiliation.
[1] Independent Researcher, Miami Beach, Fl 33139, USA
[2] Department of Microbiology, Faculty of Applied Sciences, Parul University, India

Please cite this article:
Md Shamsuddin Sultan Khan et al. (2024). Innovations in Cancer Research and Treatment, Australian Herbal Insight, 7(1), 1-12, 20050

chemotherapy. Chemotherapy, in particular, has been a cornerstone of cancer treatment for decades. However, its systemic nature and associated side effects have prompted the search for more targeted and tolerable therapies. The advent of targeted therapy marked a significant paradigm shift in cancer treatment (Baudino et al., 2015). Unlike conventional chemotherapy, targeted therapies aim to specifically inhibit molecular pathways or cellular processes involved in cancer growth and progression.

The evolution of chemotherapy can be traced back to the discovery of alkylating agents and antimetabolites, which were among the first pharmacological approaches used to treat cancer (Falzone et al., 2018). Alkylating agents, such as nitrogen mustard-based drugs, exert their cytotoxic effects by adding alkyl groups to DNA bases, leading to DNA damage and cell death. Antimetabolites, on the other hand, interfere with DNA replication by mimicking nucleotides, thereby inhibiting cell proliferation.

Over time, chemotherapy regimens evolved to include a diverse range of agents, including anti-mitotic agents, cytotoxic antibiotics, and other novel compounds targeting specific cellular processes (Falzone et al., 2018). Combination therapies emerged as a standard approach to cancer treatment, aiming to maximize efficacy while minimizing drug resistance and adverse effects (Shewach et al., 2019).

Despite its efficacy, conventional chemotherapy is associated with significant toxicity and adverse effects, underscoring the need for more refined and targeted therapeutic approaches (Schirrmacher et al., 2019). The emergence of personalized medicine and targeted therapies has revolutionized cancer treatment by enabling clinicians to tailor treatment regimens based on individual patient characteristics and tumor biology (Zugazagoitia et al., 2016).

Personalized therapy involves the use of molecular diagnostics and genetic profiling to identify specific molecular targets or biomarkers associated with cancer progression. This approach allows for the selection of targeted therapies that are most likely to be effective based on the unique genetic makeup of each patient's tumor.

In addition to personalized therapy, targeting the tumor microenvironment has emerged as a promising strategy for cancer treatment. The tumor microenvironment plays a critical role in cancer progression and metastasis, providing a supportive niche for tumor growth and evasion of the immune system. Targeting components of the tumor microenvironment, such as angiogenesis or immune checkpoints, has shown promise in enhancing the efficacy of cancer treatment (Zugazagoitia et al., 2016).

Immunotherapy represents a prime example of targeted therapy that harnesses the body's immune system to recognize and eliminate cancer cells. This approach has led to remarkable advances in the treatment of various cancers, including melanoma, lung cancer, and lymphoma. By targeting immune checkpoints or enhancing immune responses against tumors, immunotherapy offers a novel and effective therapeutic approach with fewer side effects compared to traditional chemotherapy (Zugazagoitia et al., 2016).

Another area of active research in cancer therapy is the development of cancer vaccines. Cancer vaccines aim to stimulate the body's immune system to recognize and attack cancer cells, similar to the way vaccines prevent infectious diseases. While still in early stages of development, cancer vaccines hold great promise as a preventive measure against cancer recurrence and metastasis.

Stem cell-based therapies represent yet another frontier in cancer treatment. These therapies involve the use of stem cells, either from the patient's own body or from donor sources, to regenerate healthy tissues and replace damaged or cancerous cells. While still experimental, stem cell-based therapies offer potential avenues for regenerative medicine and targeted cancer treatment.

In conclusion, the landscape of cancer therapy is rapidly evolving, driven by advances in our understanding of tumor biology and the development of novel therapeutic approaches. Personalized therapy, targeted therapy, immunotherapy, cancer vaccines, and stem cell-based therapies offer promising avenues for improving patient outcomes and reducing the burden of cancer worldwide. However, significant challenges remain, including the need for further research, access to innovative therapies, and addressing disparities in cancer care. By continuing to invest in research and innovation, we can strive towards a future where cancer is no longer a leading cause of morbidity and mortality.

In this exploration, we delve into the dynamic realm of cancer research and treatment to uncover the latest innovations reshaping our approach to this complex disease. Our goal is to provide a vivid panorama of how breakthroughs in genetic research, immunotherapy, diagnostic technologies, artificial intelligence, and novel therapeutic strategies are revolutionizing cancer care. By illuminating these advancements, we aim to showcase their potential to not only enhance patient outcomes but also usher in a new era of personalized medicine tailored to individual needs. Moreover, we seek to identify pathways for future research and development, envisioning a roadmap towards continued progress in our collective fight against cancer.

Cancer immunotherapy

Cancer immunotherapy, including targeted therapies such as immunotherapy, offers precise tumor-site treatment while sparing surrounding host cells, resulting in fewer side effects (Pucci et al., 2019). This approach harnesses the patient's immune system to attack and eliminate cancerous cells and has proven effective in various cancers, including renal cancer, lung cancer, bladder cancer, breast cancer, melanoma, and Hodgkin's lymphoma (Lee et al., 2017). Approved methods include monoclonal antibodies (mAbs), immune checkpoint blockers, cytokines, cancer vaccines,

and cell-based immunotherapy (Ventola et al., 2017), some of which can be personalized through genetic engineering (Lee et al., 2017).

Adoptive cellular therapy, such as CAR-T cells, involves transferring lymphocytes with antitumor effector function, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR)-T cells, and tumor-infiltrating lymphocytes (TILs) as show in Fig:2.

CAR-T cell

CAR-T cells, derived mainly from peripheral blood, are genetically modified to target cancer cells effectively. While CAR-T-cell therapy has shown promise against hematologic malignancies, its efficacy against solid tumors is limited due to antigenic mismatch and inhibitory microenvironments (Tang et al., 2020). Strategies to enhance CAR-T-cell function include promoting donor cells through their CARs, discovering specific antigens using tumor-targeting adenoviruses, and enriching nonviral aptamer-T cells in the tumor microenvironment (TME) (Ma et al., 2019; Liu et al., 2020). FDA-approved CAR-T-cell therapies like YESCARTA® and KYMRIAH® target CD19 to treat non-Hodgkin lymphoma or acute lymphoblastic leukemia (Zheng et al., 2018). Additionally, ABECMA®, the first BCMA-targeted CAR-T-cell therapy, has been approved for relapsed or refractory multiple myeloma (Pont et al., 2019). However, CAR-T-cell therapy can lead to severe side effects, including neurologic toxicities and cytokine release syndrome, limiting its clinical application.

CAR-T-cell therapy, a modular synthetic T-cell therapy, targets surface antigens independently of MHC and has shown success in targeting CD19 in B-cell leukemia or lymphoma (Waldman et al., 2020). Ongoing research aims to develop multi-target CAR constructs for solid tumors like melanomas, glioblastoma, and breast cancer (Sterner et al., 2021).

Monoclonal antibodies

Monoclonal antibodies have now become an integral part of cancer therapy, like chemotherapy and radiation therapy. They are small recombinant proteins developed against specifc targets, like receptors or cellular proteins (Falzone et al, 2018). These antibodies can work in multiple ways. They can use direct cytotoxic action on tumor cells or stimulate the immune system to develop anti-tumor responses (Zahavi et al, 2020). Trastuzumab was the frst mAb against human epidermal growth factor receptor 2 (HER2)/neu receptor of breast cancer being tested in a clinical trial. At the same time, rituximab targeting surface antigen CD-20 in B-cell lymphoma was the frst approved mAb (Falzone et al, 2018). To date, there have been 30 mAbs approved by FDA and/or EMA for cancer therapy (Lu et al, 2020). These antibodies have been developed against targets, like HER2 (breast cancer), epidermal growth factor receptor (EGFR, colorectal, head, and neck cancer), and CD proteins (lymphoma, melanoma) (Lee et al, 2017).

Immune checkpoint inhibitors

The tumor microenvironment serves as a physical barrier to T cells. Besides, the tumor can also afect the T-cell generation and activation and produce angiogenic and immunosuppressive factors [prostaglandin, programmed death (PD-1), PD ligand (PD-L1), cytotoxic T-lymphocyte-associated antigen (CTLA)]. These mechanisms help the cancer cells to evade the immune response and escape the T-cell immunity. The immune checkpoint inhibitors are mAbs that target these immune-suppressive mechanisms of the tumor and prevent the immune escape of the cancer cells, providing passive immunity (Sambi et al, 2019). Monoclonal antibodies, anti-CTLA, anti-PD-1, or anti-PD-L1 have shown clinical benefts in some cancers (melanoma, non-small cell lung cancer, merkel cell carcinoma, urothelial carcinoma, or renal cancer) (Lee et al, 2017). Ipilimumab was the frst FDA-approved immune checkpoint inhibitor mAb directed toward CTLA-4 for the treatment of metastatic melanoma. Later, anti-PD-1 and antiPD-L1 drugs also received approval for other solid tumors (metastatic melanoma, non-small cell lung cancer, urothelial carcinoma, head and neck cancer, or renal cancer) (Waldman et al, 2020).

Metastatic tumors were earlier difcult to be operated, as it was unlikely to provide any beneft. However, immune checkpoint inhibitors are helpful for such advanced cancer patients wherein they could reduce or eliminate the tumor to be surgically removed. Further, the response observed with these agents was remarkable and durable (Lee et al, 2017).. The efectiveness of these agents has led to the further development of other targets, such as lymphocyte activation gene 3 (LAG3), T-cell immunoglobulin and mucin domain-containing 3 (TIM3), T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), and V-domain immunoglobulin suppressor of T-cell activation (VISTA) (Zahavi et al, 2020). However, it is essential to note that the efectiveness of these agents was observed in only a minority of patients and thus, combination therapy using multiple targeted therapies may be developed (Lee et al, 2017).

Targeted Therapy Innovations

Targeted therapy innovations represent a paradigm shift in cancer treatment, leveraging our growing understanding of cancer biology to develop highly specific and effective therapies. By focusing on the molecular mechanisms driving cancer growth and progression, these therapies offer the potential to improve patient outcomes while minimizing the side effects associated with traditional treatments (Paez et al., 2014). In this exploration, we will delve into the principles behind targeted therapy, examine some of the most promising advancements in the field, and consider the future implications of this approach for cancer care.

At the heart of targeted therapy lies the recognition that cancer is not a single disease but a collection of diseases, each characterized by unique genetic mutations and molecular alterations. Traditional

chemotherapy, while effective in many cases, is often associated with significant toxicity because it indiscriminately targets rapidly dividing cells, including healthy ones. In contrast, targeted therapy seeks to exploit the specific vulnerabilities of cancer cells while sparing normal tissue, thereby maximizing efficacy and minimizing harm (National Cancer Institute, n.d.).

The development of targeted therapies begins with a deep understanding of the molecular pathways involved in cancer development and progression. Advances in genomic sequencing technologies have enabled researchers to identify key genetic mutations and aberrant signaling pathways that drive cancer growth. Armed with this knowledge, scientists can design drugs that selectively target these molecular alterations, disrupting the processes that sustain cancer cell survival and proliferation (American Cancer Society, 2023).

One of the earliest success stories in targeted therapy is the use of imatinib (Gleevec) for the treatment of chronic myeloid leukemia (CML). CML is characterized by the presence of the BCR-ABL fusion protein, which drives uncontrolled cell division. Imatinib works by specifically inhibiting the activity of the BCR-ABL protein, effectively shutting down the signaling pathway that promotes cancer growth. The introduction of imatinib marked a significant milestone in cancer treatment, demonstrating the power of targeted therapy to achieve durable responses with minimal toxicity (Druker et al., 2011).

Building on the success of imatinib, researchers have since developed a plethora of targeted therapies across a wide range of cancer types. In non-small cell lung cancer (NSCLC), for example, the discovery of activating mutations in the epidermal growth factor receptor (EGFR) led to the development of EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib. These drugs block the activity of EGFR, a key driver of NSCLC growth, resulting in improved outcomes for patients with EGFR-mutant tumors (Lynch et al., 2014).

Similarly, in melanoma, the identification of activating mutations in the BRAF gene paved the way for the development of BRAF inhibitors such as vemurafenib and dabrafenib. These drugs selectively target the abnormal BRAF protein, which is found in approximately half of all melanomas, leading to tumor regression and prolonged survival in patients with BRAF-mutant melanoma (Chapman et al., 2011; Flaherty et al., 2012).

Beyond genetic mutations, targeted therapies can also exploit other molecular vulnerabilities in cancer cells. Angiogenesis, the process by which tumors develop new blood vessels to support their growth, is a critical hallmark of cancer progression. Drugs targeting vascular endothelial growth factor (VEGF), such as bevacizumab and aflibercept, inhibit angiogenesis and have been approved for the treatment of various cancers, including colorectal, lung, and kidney cancer (Ferrara et al., 2014).

Another promising avenue in targeted therapy is the use of immunotherapy, which harnesses the power of the immune system to recognize and destroy cancer cells. Checkpoint inhibitors, such as pembrolizumab and nivolumab, block inhibitory pathways that cancer cells use to evade immune detection, unleashing an immune response against the tumor. While immunotherapy has shown remarkable efficacy in certain cancer types, not all patients respond to treatment, highlighting the need for further research to identify biomarkers predictive of response (Pardoll, 2012; Topalian et al., 2012).

Despite the successes of targeted therapy, challenges remain in translating these advances into widespread clinical benefit. Resistance to targeted therapies is a common problem, as cancer cells can develop alternate signaling pathways or acquire additional mutations that render them insensitive to treatment. Combination therapies, which target multiple pathways simultaneously, are being explored as a strategy to overcome resistance and improve treatment outcomes (Sawyers, 2004).

Moreover, the high cost of targeted therapies presents a barrier to access for many patients, particularly in low- and middle-income countries. Addressing issues of affordability and equitable access to these life-saving treatments will be crucial in ensuring that all patients can benefit from the latest advances in cancer care (World Health Organization, 2021).

Future of targeted therapy holds great promise as researchers continue to unravel the complexities of cancer biology. Advances in technology, such as single-cell sequencing and liquid biopsies, are providing new insights into tumor heterogeneity and evolution, which could inform the development of more effective targeted therapies. The emergence of novel drug delivery systems, such as nanoparticles and gene editing technologies, may also expand the therapeutic arsenal available to clinicians (Swanton, 2012; Mullard, 2020).

Furthermore, the precision oncology, which aims to tailor treatment strategies based on the unique molecular profile of each patient's tumor, is gaining traction. By integrating genomic data, clinical information, and real-time monitoring, precision oncology offers the potential to optimize treatment selection and improve outcomes for individual patients (National Institutes of Health, 2022).

In conclusion, targeted therapy innovations represent a transformative approach to cancer treatment, offering the promise of personalized therapies that target the underlying drivers of cancer growth and progression. While challenges remain, including issues of resistance and access, ongoing research efforts continue to drive progress in this field. By harnessing the power of molecular biology and cutting-edge technology, targeted therapies have the potential to revolutionize cancer care and improve outcomes for

patients worldwide (Sawyers, 2013; American Society of Clinical Oncology, 2023).

Cancer Genomics and Personalized Medicine

The landscape of cancer treatment has undergone a profound transformation in recent decades, transitioning from generalized approaches to highly individualized strategies. At the core of this evolution lies cancer genomics, a field dedicated to analyzing the genetic makeup of cancer cells. By pinpointing specific genetic abnormalities driving tumor development, oncologists can devise personalized treatment regimens tailored to each patient's unique genetic profile. This approach, known as personalized or precision medicine, holds immense potential for enhancing the effectiveness of cancer therapies and improving patient outcomes (American Cancer Society, 2023).

Genomic Sequencing and CancerGenomic sequencing entails unraveling the DNA of cancer cells to identify mutations, amplifications, deletions, and other genetic alterations contributing to cancer progression. Next-generation sequencing (NGS) technologies have revolutionized this process, enabling rapid and cost-effective analysis of cancer genomes. These technologies furnish detailed insights into the genetic landscape of tumors, unveiling actionable mutations that can be targeted with specific therapies (Mayo Clinic, 2023).A significant advantage of genomic sequencing in cancer treatment is its ability to unveil the heterogeneity of tumors.

Cancers comprise diverse cell populations with distinct genetic profiles, which can foster treatment resistance and disease recurrence. By scrutinizing the genetic composition of tumors at a granular level, clinicians can identify predominant genetic alterations and devise treatment plans tailored to target these specific changes (Ellert-Miklaszewska et al , 2020).

Targeted Therapies and Genetic Alterations

Targeted Therapies and Genetic AlterationsTargeted therapies constitute a cornerstone of personalized cancer treatment, aiming to disrupt specific molecules involved in cancer cell proliferation and survival with greater precision and fewer side effects than conventional chemotherapy. The success of targeted therapies hinges upon identifying actionable genetic alterations within tumors.For instance, mutations in the EGFR (epidermal growth factor receptor) gene drive the growth of non-small cell lung cancer (NSCLC). Patients harboring these mutations often respond favorably to EGFR inhibitors such as erlotinib and gefitinib, which obstruct the signaling pathways activated by the mutant EGFR protein. Similarly, breast cancers characterized by HER2 protein overexpression, attributable to ERBB2 gene amplification, can be effectively treated with HER2-targeted therapies like trastuzumab and pertuzumab (Cancer Research UK, 2023).

Another notable example is the identification of BRAF mutations in melanoma. Approximately 50% of melanomas exhibit mutations in the BRAF gene, promoting uncontrolled cell proliferation. The advent of BRAF inhibitors such as vemurafenib and dabrafenib has substantially improved the prognosis for patients with BRAF-mutant melanoma (Kumaki et al, 2023).

Immunotherapy and Genomic Profiling

In addition to targeted therapies, personalized medicine has revolutionized immunotherapy. Immunotherapies, including immune checkpoint inhibitors, harness the body's immune system to combat cancer cells. However, the efficacy of these treatments varies among patients, and genomic profiling can aid in identifying those most likely to benefit.Tumors exhibiting high levels of microsatellite instability (MSI) or defects in mismatch repair (MMR) genes are more responsive to immune checkpoint inhibitors such as pembrolizumab and nivolumab. These genetic alterations instigate a high mutational burden, resulting in the production of neoantigens that render the tumor more recognizable to the immune system (Journal of Clinical Oncology, 2017).

Moreover, genomic sequencing can identify other predictive biomarkers for immunotherapy response, such as PD-L1 expression and tumor mutational burden (TMB), guiding treatment decisions and ensuring patients receive the most suitable therapies (American Cancer Society, 2023).

Metastasis Inhibition Strategies

Metastasis, the spread of cancer cells from a primary tumor to secondary sites, remains the leading cause of cancer-related mortality. Addressing this challenge necessitates a comprehensive understanding of the mechanisms underlying metastasis and the development of innovative strategies to inhibit this process. The tumor microenvironment (TME) plays a crucial role in cancer metastasis, comprising a dynamic network of stromal cells, immune cells, extracellular matrix (ECM), and signaling molecules that interact with cancer cells to promote invasion and dissemination. Notably, cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are significant in remodeling the ECM and promoting tumor growth and metastasis (Pickup et al., 2014; Quail & Joyce, 2013).

Epithelial-Mesenchymal Transition (EMT) is another key process by which epithelial cancer cells lose their cell-cell adhesion properties and gain mesenchymal traits, enhancing their migratory and invasive capabilities. Critical signaling pathways, such as TGF-β, Wnt, and Notch, regulate EMT and contribute to the metastatic potential of cancer cells (Thiery et al., 2019). Additionally, cancer cells that detach from the primary tumor and enter the bloodstream or lymphatic system, known as circulating tumor cells (CTCs), can survive in circulation, evade immune detection, and eventually colonize distant organs, leading to secondary tumor formation (Cristofanilli et al., 2004). The process of extravasation involves CTCs adhering to and penetrating the endothelial barrier of distant organs. Once extravasated, cancer cells adapt to the new

microenvironment and establish metastatic colonies, influenced by various factors, including cell surface receptors, adhesion molecules, and the local immune response (Nieto et al., 2016).The formation of new blood vessels, or angiogenesis, is critical for tumor growth and metastasis.

Angiogenic factors like vascular endothelial growth factor (VEGF) promote the development of new blood vessels, providing tumors with the necessary nutrients and pathways for dissemination (Folkman, 2002). Targeting these mechanisms offers potential therapeutic strategies to inhibit metastasis. One approach is the inhibition of EMT, where targeting pathways such as TGF-β, Wnt, and Notch can prevent cancer cells from acquiring invasive properties. Small molecule inhibitors, monoclonal antibodies, and RNA-based therapies are being explored to inhibit EMT and reduce metastatic potential (Heldin et al., 2012).Another promising strategy is the capture and eradication of CTCs.

Techniques to detect and eliminate CTCs in the bloodstream are crucial for preventing metastasis. Microfluidic devices and immunoaffinity-based methods are used to capture CTCs, while targeted therapies, such as antibody-drug conjugates, are employed to destroy them (Gorges & Pantel, 2013). Anti-angiogenic drugs, such as bevacizumab (an anti-VEGF antibody), inhibit the formation of new blood vessels, starving tumors of nutrients and reducing their metastatic potential. These therapies can be used alone or in combination with other treatments to enhance efficacy (Folkman, 2002).Modulating the immune system to recognize and attack metastatic cancer cells is also a promising strategy. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, have shown success in reinvigorating T cells to target cancer cells. Additionally, CAR-T cell therapy involves engineering a patient's T cells to express chimeric antigen receptors (CARs) that specifically target cancer cells (June et al., 2018).

Inhibiting molecules involved in cancer cell adhesion and migration, such as integrins and matrix metalloproteinases (MMPs), can prevent cancer cells from invading surrounding tissues and spreading to distant sites. Small molecule inhibitors and monoclonal antibodies targeting these molecules are under investigation (Desgrosellier & Cheresh, 2010).Modifying the tumor microenvironment to make it hostile to cancer cells can also inhibit metastasis. Strategies include altering the ECM composition, targeting stromal cells, and modulating immune components within the TME to enhance anti-tumor responses (Nakashima et al., 2020).

Cancer cells often exhibit altered metabolism to support their rapid growth and survival. Targeting metabolic pathways specific to cancer cells, such as glycolysis and glutaminolysis, can disrupt their energy supply and inhibit metastatic growth (DeBerardinis & Chandel, 2016).Gene editing technologies, like CRISPR/Cas9, offer the potential to directly target and knock out genes essential for metastasis. This approach allows for precise and efficient modification of the cancer genome to reduce metastatic potential (Zhang et al., 2017). Exosomes, small vesicles secreted by cancer cells, play a role in cell-cell communication and metastasis. Inhibiting exosome production, release, or uptake can disrupt these communication pathways and reduce metastatic spread (Kalluri, 2016).

Nanoparticles offer a targeted delivery system for anti-metastatic drugs, minimizing side effects and improving therapeutic efficacy. These systems can be engineered to deliver drugs specifically to cancer cells, enhancing drug concentration at the tumor site while sparing normal tissues (Mitchell et al., 2021).Recent advancements have further propelled the fight against metastasis. Precision medicine involves tailoring treatments based on the genetic profile of an individual's cancer. By identifying specific mutations and pathways involved in metastasis, targeted therapies can be developed to inhibit these processes.

Advances in genomic sequencing and bioinformatics have enabled more precise targeting of metastatic pathways (Dienstmann et al., 2017). Patient-derived organoids, three-dimensional cell culture systems, provide a platform to study metastasis and test anti-metastatic drugs in a controlled laboratory environment. These models more accurately reflect the complexity of human tumors, allowing for better preclinical testing of therapies (Huch et al., 2017). AI-driven algorithms can predict metastatic patterns, identify potential therapeutic targets, and analyze large datasets to uncover novel insights into metastasis. Machine learning techniques are being used to improve the accuracy of diagnostic tools and develop personalized treatment plans (Esteva et al., 2019).

Radiomics and Imaging Biomarkers

Radiomics is an emerging field that involves extracting a large number of quantitative features from medical images using advanced computational algorithms. These features, often referred to as imaging biomarkers, can provide detailed information about the tumor phenotype and microenvironment that is not visible to the naked eye. By analyzing these features, researchers and clinicians can gain insights into disease characteristics, treatment response, and progression, leading to more personalized and effective patient care (Lambin et al., 2012).

Modern imaging modalities such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) are the backbone of radiomics. These techniques offer high-resolution, three-dimensional views of anatomical structures and are capable of capturing various tissue characteristics through different imaging sequences and parameters. MRI provides excellent soft tissue contrast and can be used to assess tissue composition, vascularity, and cellularity. CT is widely used for its ability to provide detailed images of bone

structures and for its role in lung cancer screening and staging. PET imaging, often combined with CT (PET/CT), can reveal metabolic activity and molecular processes in tissues (Gillies, Kinahan, & Hricak, 2016).

The radiomics workflow typically involves several key steps. First, high-quality images are obtained using standardized imaging protocols. Second, tumors or regions of interest (ROI) are delineated manually or using automated/semi-automated tools. Third, quantitative features are extracted from the segmented ROIs. These features can be categorized into different groups such as shape, texture, intensity, and wavelet features. Fourth, advanced statistical methods and machine learning algorithms are used to analyze the extracted features. This analysis can identify patterns and correlations that may serve as potential biomarkers. Finally, predictive models are validated using independent datasets to ensure their robustness and generalizability (Aerts et al., 2014).

Imaging biomarkers derived from radiomics can serve several purposes. By analyzing pre-treatment imaging data, radiomics can help predict how a tumor will respond to specific therapies. For instance, certain texture features on MRI might correlate with tumor aggressiveness and likelihood of responding to chemotherapy. Radiomics can track changes in tumor characteristics over time, providing insights into disease progression or recurrence. Subtle changes in imaging features may indicate early signs of progression before they are detectable through conventional methods. Furthermore, radiomics can identify imaging features that are associated with patient outcomes, helping to stratify patients into different risk categories and guide treatment decisions (Parmar et al., 2015).

Despite its potential, radiomics faces several challenges. Variability in imaging acquisition protocols and feature extraction methods can affect the reproducibility of radiomics studies. Efforts are needed to standardize protocols and establish robust, reproducible workflows. For radiomics to be widely adopted, it must be integrated seamlessly into clinical workflows. This requires collaboration between radiologists, oncologists, and data scientists. Additionally, large, diverse datasets are essential for developing and validating robust radiomics models. Encouraging data sharing and collaboration across institutions can accelerate the advancement of this field (Yip & Aerts, 2016).

Epigenetic Therapies in Cancer

Epigenetic therapies in cancer are emerging as a promising avenue for more effective treatments. Epigenetic modifications, which orchestrate gene expression without altering the DNA sequence, are pivotal in cancer progression, influencing key cellular processes (Jones, Issa, & Baylin, 2016). Aberrant DNA methylation, histone modifications, and non-coding RNA-mediated mechanisms contribute significantly to the dysregulated gene expression observed in cancer cells, motivating the development of therapies aimed at rectifying these alterations and reinstating normal cellular function (Baylin et al, 2016).

DNA methylation is a well-studied epigenetic modification in cancer, involving the addition of methyl groups to cytosine bases in DNA. Hypermethylation of CpG islands within gene promoter regions can silence tumor suppressor genes, while global hypomethylation can lead to genomic instability and activation of oncogenes (Issa, & Baylin, 2016). Similarly, histone modifications, such as acetylation, methylation, phosphorylation, and ubiquitination, exert critical roles in chromatin structure and gene regulation. Disruptions in histone modifications can perturb normal chromatin organization, contributing to aberrant gene expression patterns in cancer.To address these epigenetic alterations, researchers have developed targeted therapies, including DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis) (Flavahan et al, 2017).

DNMTis like azacitidine and decitabine function by integrating into DNA during replication, leading to DNA demethylation and reactivation of silenced tumor suppressor genes. Conversely, HDACis such as vorinostat and romidepsin inhibit histone deacetylase enzymes, inducing hyperacetylation of histone proteins and consequently activating genes involved in cell cycle arrest, apoptosis, and differentiation (Huang et al, 2021). Despite notable advancements in epigenetic drug development, challenges persist in tailoring treatments to individual patients and optimizing therapeutic efficacy. Further investigation into patient-specific epigenetic alterations and the underlying molecular mechanisms of epigenetic dysregulation in cancer is crucial for refining personalized treatment strategies and enhancing patient outcomes (Yang et al, 2010).

Microbiome and Cancer Interaction

The relationship between the microbiome and cancer is a burgeoning field of research, uncovering its profound influence on cancer development, progression, and treatment outcomes. Studies have elucidated intricate interactions between the gut microbiota and cancer biology, emphasizing the need to comprehend these dynamics for refining cancer management strategies.

The microbiome's impact on cancer includes its role in modulating inflammation, a known driver of cancer initiation and progression. Through the production of metabolites like lipopolysaccharides and peptidoglycans, the gut microbiota can sustain a pro-inflammatory environment, activating immune responses and oncogenic signaling pathways (Arthur et al., 2012).Moreover, dysbiosis, characterized by microbial imbalance, has been implicated in promoting carcinogenesis. Changes in specific bacterial taxa within the gut microbiota are associated with increased cancer risk, notably colorectal cancer (Tilg et al., 2020).

Dysbiotic microbiota can promote tumorigenesis via genotoxic metabolites, inducing DNA damage and epithelial cell proliferation



Figure 1. Rate of Cancer Burden



Figure 2. Adoptive cellular therapy. Adoptive cellular therapy includes the use of chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR), T cells, or tumor-infiltrating lymphocytes (TILs) [Color figure can be viewed at (Wileyonlinelibrary.com).

Table 1. Various novel therapy approaches

Treatment Modality	Description	Examples	Mechanism of Action	Cancer Types
Chemotherapy	Systemic treatment using drugs to kill cancer cells, often associated with significant toxicity and side effects.	Alkylating agents, antimetabolites	Induces DNA damage, inhibits cell division.	Various
Targeted Therapy	Selectively targets molecular pathways or cellular processes involved in cancer growth and progression	Imatinib (Gleevec), EGFR inhibitors	Blocks specific signaling pathways	Specific molecular targets

Table 1. Various novel therapy approaches

Treatment Modality	Description	Examples	Mechanism of Action	Cancer Types
Chemotherapy	Systemic treatment using drugs to kill cancer cells, often associated with significant toxicity and side effects.	Alkylating agents, antimetabolites	Induces DNA damage, inhibits cell division.	Various
Targeted Therapy	Selectively targets molecular pathways or cellular processes involved in cancer growth and progression	Imatinib (Gleevec), EGFR inhibitors	Blocks specific signaling pathways	Specific molecular targets
Immunotherapy	Harnesses the body's immune system to recognize and eliminate cancer cells, offering a novel and effective approach	Checkpoint inhibitors, CAR-T cells	Enhances immune response against tumors	Various, including melanoma, lung cancer
Cancer Vaccines	Stimulates the body's immune system to recognize and attack cancer cells, similar to preventive vaccines	In early stages of development	Trains immune system to target cancer cells	Various
Stem Cell-Based Therapies	Uses stem cells to regenerate healthy tissues and replace damaged or cancerous cells, offering potential for targeted treatment	Experimental, potential regenerative medicine	Regenerates damaged tissues and cells	Various

(Arthur et al., 2012).The gut microbiota also influences cancer treatment efficacy. Certain bacterial species enhance immune checkpoint inhibitor efficacy by priming antitumor immune responses (Gopalakrishnan et al., 2018). Conversely, dysbiotic microbiota can contribute to treatment resistance and worsen therapy-related side effects like gastrointestinal toxicity and immunotherapy-induced colitis (Wang et al., 2019).

Recognizing the microbiome's potential as a therapeutic target, researchers explore strategies to modulate it for better treatment outcomes. These include dietary interventions, probiotics, prebiotics, and fecal microbiota transplantation. Studies demonstrate the feasibility and efficacy of these approaches in enhancing antitumor immunity, reducing treatment-related toxicity, and inhibiting tumor growth (Roy and Trinchieri, 2017).

Artificial Intelligence in Oncology

Artificial Intelligence (AI) and machine learning (ML) have emerged as critical drivers in advancing oncology, significantly improving cancer diagnosis, treatment planning, and prediction of treatment outcomes. These technologies harness extensive datasets and intricate algorithms to extract valuable insights and patterns from diverse data sources.In the domain of medical imaging, AI demonstrates remarkable capabilities in augmenting the accuracy and efficiency of cancer detection.

For instance, Esteva et al. (2017) illustrated the effectiveness of a convolutional neural network (CNN) in classifying skin lesions with accuracy comparable to dermatologists. Similarly, Ardila et al. (2019) highlighted the potential of AI algorithms in detecting lung nodules on chest radiographs, facilitating early diagnosis of lung cancer.Furthermore, AI-driven approaches are reshaping treatment planning by offering personalized strategies for cancer patients. Liu et al. (2018) explored machine learning techniques to predict individual responses to chemotherapy based on genomic signatures, providing insights into treatment efficacy and potential adverse effects. Additionally, in radiation oncology, AI algorithms optimize treatment delivery and target localization, as evidenced by studies such as that by Boldrini et al. (2019).

Moreover, AI holds promise in predicting treatment outcomes and patient survival rates by integrating multi-modal data and clinical parameters. For example, Ching et al. (2018) developed a deep learning model capable of predicting overall survival in glioma patients using MRI images and clinical data. Similarly, Kourou et al. (2015) reviewed the application of machine learning techniques in cancer prognosis, emphasizing their potential to improve risk stratification and treatment decision-making.Despite these advancements, challenges like data standardization, algorithm interpretability, and regulatory considerations persist. Addressing these issues through interdisciplinary collaboration and robust validation methodologies is essential to ensure the safe and effective integration of AI into clinical practice.

Combination Therapies for Cancer

Combination therapy stands as a pivotal approach in the realm of cancer treatment, offering a multifaceted strategy to combat the complexities of cancer progression. By combining two or more immunotherapies or integrating immunotherapy with traditional chemotherapies, this approach aims to simultaneously target multiple pathways involved in cancer development and spread. The amalgamation of different therapeutic modalities holds the promise of enhancing overall survival rates and bolstering the response rates in cancer patients (Waldman et al, 2022).

In recent years, a plethora of combination therapies has emerged, each tailored to address the unique characteristics of various cancer types. Among these combinations are immune checkpoint inhibitors administered in tandem with other checkpoint inhibitors, such as pairing anti-CTLA-4 with anti-PD-1/PD-L1 monoclonal antibodies. Additionally, therapies like ipilimumab and nivolumab have been combined with conventional chemotherapy agents like carboplatin, paclitaxel, or cisplatin, as well as with radiotherapy, to potentially amplify their efficacy (Barbari et al, 2020).

Another innovative approach involves combining chimeric antigen receptor T-cell (CAR-T cell) therapy with checkpoint inhibitors, such as pembrolizumab or nivolumab, to capitalize on their complementary mechanisms of action. Furthermore, researchers are exploring the synergy between cancer vaccines and chemotherapy, exemplified by the integration of peptide-based cancer vaccines with agents like cyclophosphamide, particularly in the context of renal cell carcinoma (Sterner et al, 2021).

The significance of combination therapy has been underscored by the approval of certain regimens by regulatory agencies like the FDA. Notably, the combination of ipilimumab and nivolumab has garnered FDA approval for the treatment of metastatic melanoma and renal cell carcinoma, reflecting the clinical validation of this approach (Camarero et al, 2012).

Looking ahead, the landscape of cancer treatment is poised for further transformation through the continued exploration and refinement of combination therapies. While significant strides have been made in certain cancer types, there remains a vast frontier of unmet medical needs awaiting innovative therapeutic interventions. By harnessing the synergistic potential of diverse treatment modalities, combination therapies offer a compelling avenue for advancing the standard of care across a spectrum of cancers. As ongoing research endeavors shed light on novel combinations and treatment regimens, the future holds promise for unlocking new therapeutic horizons and improving outcomes for cancer patients worldwide.

Author contributions

M.A.S., M.S.S.K., and T. contributed equally to this work. M.A.S. conceived the study, designed the experiment, and wrote the initial draft of the manuscript. M.S.S.K. conducted the data analysis and interpretation. T. provided critical revisions to the manuscript and assisted with data collection. All authors reviewed and approved the final version of the manuscript.

Acknowledgment

Author was grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Aerts, H. J., Velazquez, E. R., Leijenaar, R. T., Parmar, C., Grossmann, P., Carvalho, S., ... & Lambin, P. (2014). Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications, 5, 4006.

Ardila, D., et al. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25(6), 954-961

Arthur, J. C., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120-123.

Azuaje, F. (2019). Computational models for predicting drug responses in cancer research. Briefings in Bioinformatics, 20(2), 450-459.

Baylin, S. B., & Jones, P. A. (2016). Epigenetic therapy: a new weapon in the war against cancer. The Journal of Clinical Investigation, 126(6), 2160-2169.

Boldrini, L., et al. (2019). Artificial intelligence and radiomics in oncology: A user's guide. La Radiologia Medica, 124(6), 512-532.

Calin, G. A., & Croce, C. M. (2016). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6(11), 857-866.

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., ... & McArthur, G. A. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26), 2507-2516.

Ching, T., et al. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of The Royal Society Interface, 15(141), 20170387.

Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y. X. (2014). Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. Journal of Clinical Investigation, 124(2), 687-695.

Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., ... & Sawyers, C. L. (2011). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344(14), 1031-1037.

Esteva, A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115-118.

Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2014). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery, 3(5), 391-400.

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., ... & Weber, J. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine, 367(18), 1694-1703.

Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357(6348), eaal2380.

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., ... & KEYNOTE-189 Investigators. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. New England Journal of Medicine, 378(22), 2078-2092.

Garzon, R., Calin, G. A., & Croce, C. M. (2010). MicroRNAs in Cancer. Annual Review of Medicine, 60(1), 167-179.

Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016). Radiomics: images are more than pictures, they are data. Radiology, 278(2), 563-577.

Gopalakrishnan, V., et al. (2018). Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97-103.

Greer, E. L., & Shi, Y. (2012). Histone methylation: a dynamic mark in health, disease and inheritance. Nature Reviews Genetics, 13(5), 343-357.

Hegde, P. S., & Chen, D. S. (2020). Top 10 challenges in cancer immunotherapy. Immunity, 52(1), 17-35.

Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: an overview. Cancers, 6(3), 1769-1792.

Huang, Y., Zhang, J., Hou, L., & Wang, G. (2021). The role of DNA methylation in the development and treatment of cancer. Aging and Disease, 12(6), 1696-1712.

Jin, H., Wang, L., & Bernards, R. (2023). Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 22(3), 213-234.

Jones, P. A., & Baylin, S. B. (2017). The epigenomics of cancer. Cell, 128(4), 683-692.

Keefe, D. M., & Bateman, E. H. (2019). Potential successes and challenges of targeted cancer therapies. JNCI Monographs, 2019(53), lgz008.

Kizub, D. A., Naik, S., Abogan, A. A., Pain, D., Sammut, S., Shulman, L. N., & Martei, Y. M. (2022). Access to and Affordability of world health organization essential medicines for cancer in sub-Saharan Africa: examples from Kenya, Rwanda, and Uganda. The oncologist, 27(11), 958-970.

Kourou, K., et al. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8-17.

Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R. G., Granton, P., ... & Dekker, A. (2012). Radiomics: extracting more information from medical images using advanced feature analysis. European Journal of Cancer, 48(4), 441-446.

Lawler, M., Davies, L., Oberst, S., Oliver, K., Eggermont, A., Schmutz, A., ... & Sullivan, R. (2023). European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission. The Lancet Oncology, 24(1), e11-e56.

Liu, Y., et al. (2018). An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell, 173(2), 400-416.

Lu, C. Y., Terry, V., & Thomas, D. M. (2023). Precision medicine: affording the successes of science. NPJ Precision Oncology, 7(1), 3.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., ... & Haber, D. A. (2014). Activating mutations in the epidermal growth factor

receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129-2139.

Marks, P. A. (2010). The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opinion on Investigational Drugs, 19(9), 1049-1066.

Mullard, A. (2020). Stemming the tide of drug resistance in cancer. Nature reviews Drug discovery, 19(4), 221-224.

Paez, J. G., et al. (2014). EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science.

Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature reviews cancer, 12(4), 252-264.

Parmar, C., Grossmann, P., Rietveld, D., Rietbergen, M. M., Lambin, P., & Aerts, H. J. (2015). Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer. Frontiers in Oncology, 5, 272.

Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2019). Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology, 30(6), 1010–1022.

Roy, S., & Trinchieri, G. (2017). Microbiota: a key orchestrator of cancer therapy. Nature Reviews Cancer, 17(5), 271-285.

Sawyers, C. (2014). Targeted cancer therapy. Nature, 432(7015), 294-297.

Sawyers, C. L., Abate-Shen, C., Anderson, K. C., Barker, A., Baselga, J., Berger, N. A., … & Weiner, G. J. (2013). AACR cancer progress report 2013. Clinical cancer research, 19(20_Supplement), S1-S98.

Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015). Radiation and checkpoint blockade immunotherapy: radiosensitization and potential mechanisms of synergy. The Lancet Oncology, 16(13), e498-e509.

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., ... & Settleman, J. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141(1), 69-80.

Swanton, C. (2012). Intratumor heterogeneity: evolution through space and time. Cancer research, 72(19), 4875-4882.

Tilg, H., et al. (2020). The intestinal microbiota in colorectal cancer. Cancer Cell, 33(6), 954-964.

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., ... & Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443-2454.

Wang, Y., et al. (2019). Fecal microbiota transplantation for refractory immune checkpoint inhibitor–associated colitis. Nature Medicine, 25(8), 1234-1236.

Weissleder, R., & Pittet, M. J. (2008). Imaging in the era of molecular oncology. Nature.

Wolf, A., Oeffinger, K. C., Shih, T. Y. C., Walter, L. C., Church, T. R., Fontham, E. T., ... & Smith, R. A. (2023). Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians.

Yang, A. S., Doshi, K. D., Choi, S. W., Mason, J. B., Mannari, R. K., Gharybian, V., ... & Jones, P. A. (2010). DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Research, 66(10), 5495-5503.

Yip, S. S., & Aerts, H. J. (2016). Applications and limitations of radiomics. Physics in Medicine & Biology, 61(13), R150.